Enzo Biochem, Inc. (NYSE:ENZ)

CAPS Rating: 1 out of 5

The Company is a life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and a provider of diagnostic services to the medical community.


Player Avatar zzlangerhans (99.85) Submitted: 2/25/2013 6:05:35 AM : Underperform Start Price: $3.06 ENZ Score: +10.39

Enzo may have been awarded 49M in a patent infringement suit against Life Technologies, but that cash isn't in the bank yet. Aside from appeals and other machinations that may delay Enzo's receipt of the award, Enzo still has static revenues and negative cash flow. The stock has had a nice comeback from last summer's lows around 1.5 but I think it's getting a little ahead of itself over 3.

Featured Broker Partners